Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection

AIDS

Volumn 26, Issue 7, 2012, Pages 861-865

  Okosun, Jessica ^a   Warbey, Victoria ^b   Shaw, Kate ^c   Montoto, Silvia ^d   Fields, Paul ^b   Marcus, Robert ^e   Virchis, Andres ^a   McNamara, Christopher ^a   Bower, Mark ^c   Cwynarski, Kate ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

adriamycin; bleomycin; fluoro 2 deoxy D glucose PET; HIV; Hodgkin lymphoma; vinblastine and dacarbazine therapy

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VINBLASTINE;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLEOMYCIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VINBLASTINE;

EID: 84859977672     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835213b1     Document Type: Article

References (23)

1. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52:611-622.
2. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. HIV/AIDS Cancer Match Study: trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645-1654. (Pubitemid 44162407)
3. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol 2007; 60:1365-1372. (Pubitemid 350247252)
4. Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS 2009; 4:3-10.
5. Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C, Nigra E, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100:1984-1988. (Pubitemid 35001227)
6. Xicoy B, Ribera J-M, Miralles P, Berenguer J, Rubio R, Mahillo B, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007; 92:191-198.
7. Hartmann P, Rehwald U, Salzberger B, Franzen C, Sieber M, Wöhrmann A, et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 2003; 14:1562-1569. (Pubitemid 37304614)
8. Spina M, Rossi G, Antinori A, Allione B, Chimienti E, Talamini R, Tirelli U. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV) [abstract]. Ann Oncol 2008; 19 (Suppl 4):iv 152.
9. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91:475-481.
10. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107:52-59. (Pubitemid 43053523)
11. Swerdlow SH, Campo E, editors.WHOclassification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC; 2008.
12. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-1514.
13. Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy. HIV Med 2008; 9:563-608.
14. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-586. (Pubitemid 350002966)
15. Meignan M, Gallamini M, Haioun C, Polliack A. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010; 51:2171-2180.
16. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25:3746-3752. (Pubitemid 47372616)
17. Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with an interim-PET positive after two ABVD courses. Br J Haematol 2011; 152:551-560.
18. Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine and dacarbazine with granulocyte-colony stimulating factor in HIV-infected patients with newly diagnosed Hodgkins' disease: a prospective, multiinstitutional AIDS Clinical Trials Group Study (ACTG149). J Acquir Immune Defic Syndr 2000; 24:444-450.
19. Cheung MC, Hicks LK, Leitch HA. Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10:E22-E25.
20. Cingolani A, Torti L, Pinnetti C, de Gaetano Donati K, Murri R, Tacconelli E, et al. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIVinfected patients with Hodgkin's lymphoma. AIDS 2010; 24:2408-2412.
21. Brust D, Polis M, Davey R, Hahn B, Bacharach S, Whatley M, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS 2006; 20:985-993.
22. Scharko AM, Perlman SB, Pyzalski RW, Graziano FM, Sosman J, Pauza CD. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet 2003; 362:959-961. (Pubitemid 37159292)
23. Goshen E, Davidson T, Avigdor A, Zwas TS, Levy I. PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med 2008; 33:610-614.